

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/527,496
				Int'l Filing Date	September 12, 2003
				First Named Inventor	Tahara, Hideaki
				Art Unit	1644
				Examiner Name	Phuong Huynh
Sheet	1	of	3	Attorney Docket Number	082368-003200US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^o
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
/PH/	AA	WO	94/21679	A1	09-29-1994	Merck & Co., Inc.		<input type="checkbox"/>
	AB	WO	98/11223	A1	03-19-1998	Schering Aktiengesellschaft		<input type="checkbox"/>
	AC	WO	98/31794	A1	07-23-1998	Toa Gosei Co., Ltd.		<input checked="" type="checkbox"/>
	AD	WO	99/40118	A1	08-12-1999	Kyowa Hakko Kogyo Co., Ltd.		<input type="checkbox"/>
	AE	WO	99/43801	A1	09-02-1999	Cancer Research Campaign Technology Limited		<input type="checkbox"/>
	AF	WO	99/59836	A1	11-25-1999	Kyowa Hakko Kogyo Co., Ltd.		<input type="checkbox"/>
	AG	WO	02/056907	A2/A3	07-25-2002	Cytos Biotechnology AG; and Novartis Pharma AG		<input type="checkbox"/>
	AH	WO	03/088450	A1	10-23-2003	Centro de Ingenieria Genetica y Biotecnologia		<input type="checkbox"/>
	AI	EP	0 921 193	A1	06-09-1999	Archibald James Mixson		<input type="checkbox"/>
	AJ	EP	1 502 599	A1	02-02-2005	Centro de Ingenieria Genetica y Biotecnologia		<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature	/Phuong Huynh/	Date Considered	10/15/2007
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/527,496
				Int'l Filing Date	September 12, 2003
				First Named Inventor	Tahara, Hideaki
				Art Unit	
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	082368-003200US


NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
/PH/	AK	BICKNELL, Roy <i>et al.</i> ; "Mechanisms and therapeutic implications of angiogenesis"; <u>Current Opinion in Oncology</u> ; 1996; pp. 60-65; Vol. 8	<input type="checkbox"/>		
	AL	BINÉTRUY-TOURNAIRE, Roselyne <i>et al.</i> ; "Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis"; <u>The EMBO Journal</u> ; 2000; pp. 1525-1533; Vol. 19, No. 7	<input type="checkbox"/>		
	AM	FOLKMAN, Judah; "Angiogenesis in cancer, vascular rheumatoid and other disease"; <u>Nature Medicine</u> ; 1995; pp. 27-31; Vol. 1, No. 1	<input type="checkbox"/>		
	AN	HUANG, Xiaojun <i>et al.</i> ; "Combined Therapy of Local and Metastatic 4T1 Breast Tumor in Mice Using SU6668, an Inhibitor of Angiogenic Receptor Tyrosine Kinases, and the Immunostimulator B7.2-IgG Fusion Protein"; <u>Cancer Research</u> ; October 15, 2002; pp. 5727-5735; Vol. 62	<input type="checkbox"/>		
	AO	KONDO, Akihiro <i>et al.</i> ; "Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules"; <u>The Journal of Immunology</u> ; 1995; pp. 4307-4312; Vol. 155	<input type="checkbox"/>		
	AP	KUBO, Ralph T. <i>et al.</i> ; "Definition of Specific Peptide Motifs for Four Major HLA-A Alleles"; <u>Journal of Immunology</u> ; 1994; pp. 3913-3924; Vol. 152	<input type="checkbox"/>		
	AQ	LI, Yiwen <i>et al.</i> ; "Active Immunization Against the Vascular Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and Metastasis"; <u>J. Exp. Med.</u> ; June 17, 2002; pp. 1575-1584; Vol. 195, No. 12	<input type="checkbox"/>		
	AR	NORGREN, R.B. <i>et al.</i> ; "Kinase insert domain receptor"; June 1, 2002; EMBL Accession No. Q8SPP1	<input type="checkbox"/>		
	AS	RAMMENSEE, Hans-Georg <i>et al.</i> ; "MHC ligands and peptide motifs: first listing"; <u>Immunogenetics</u> ; 1995; pp. 178-228; Vol. 41	<input type="checkbox"/>		
	AT	WADA, Satoshi <i>et al.</i> ; "Development of cancer vaccine targeting tumor angiogenesis"; <u>Cancer Science (Proceedings of the 62nd Annual Meeting of the Japanese Cancer Association)</u> ; September 25-27, 2003, p. 202; Abstract 2267-OP	<input checked="" type="checkbox"/>		
	AU	WADA, <i>et al.</i> ; "Development of a new type of cancer immunotherapy that targets tumor angiogenesis"; <u>The Japanese Journal of Gastroenterological Surgery</u> ; 2003, p. 564, Abstract PP-2-606; Vol. 38, No. 7	<input checked="" type="checkbox"/>		
	AV	WADA <i>et al.</i> ; "Development of a cancer vaccine therapy that targets tumor angiogenesis"; <u>Journal of the Japanese Surgical Society</u> ; 2003; pg. 533, Abstract PS3124-3; Vol. 104(Suppl.)	<input checked="" type="checkbox"/>		

Examiner Signature	/Phuong Huynh/	Date Considered	10/15/2007
--------------------	----------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/527,496		
		Int'l Filing Date	September 12, 2003		
		First Named Inventor	Tahara, Hideaki		
		Art Unit			
		Examiner Name			
Sheet	3	of	3	Attorney Docket Number	082368-003200US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/PH/ 	AW	WADA, Satoshi <i>et al.</i> ; "Development of cancer immunotherapy against tumor angiogenesis"; <u>Proceedings of the 94th Annual Meeting of the American Association for Cancer Research</u> ; July 11-14, 2003; pg. 167, Abstract 848; Washington D.C. (The previously scheduled meeting on April 5-9, 2003 in Toronto, Canada was postponed. A copy of the program from the April meeting is also enclosed)	<input checked="" type="checkbox"/>
	AX	WADA, Satoshi <i>et al.</i> ; "Development of the new cancer vaccine treatment that can be opposed to escape mechanism of immunological"; <u>Cancer Science (Proceedings of the 63rd Annual Meeting of the Japanese Cancer Association)</u> ; September 29 - October 1, 2004, p. 438, Abstract W-464; Vol. 95(Suppl)	<input checked="" type="checkbox"/>
	AY	WADA, Satoshi <i>et al.</i> ; "Rationale for Antiangiogenic Cancer Therapy with Vaccination Using Eiptope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 2"; <u>Cancer Res.</u> ; June 1, 2005; pp. 4939-4936; Vol. 65, No. 11	<input type="checkbox"/>
	AZ	WALTENBERGER, Johannes <i>et al.</i> ; "Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor"; <u>The Journal of Biological Chemistry</u> ; October 28, 1994; pp. 26988-26995; Vol. 269, No. 43	<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature	/Phuong Huynh/	Date Considered	10/15/2007
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.